Grifols Faces Calls to Terminate Canada Plasma Contracts Over Safety Concerns

Spanish pharmaceutical giant Grifols is facing mounting pressure in Canada as health coalitions in Ontario and Manitoba demand the immediate termination of its for-profit contracts. The calls for action follow disturbing reports of two patient deaths in Winnipeg and a lawsuit alleging a patient suffered kidney damage due to equipment failure during plasma harvesting. Official inspection reports from Health Canada have further intensified the scrutiny, revealing non-compliance at four Grifols centers across Calgary, Saskatoon, Regina, and St. John. Health advocacy groups are now insisting on the full disclosure of safety data while expressing grave concerns over the privatization of plasma collection. These regulatory breaches and legal challenges pose significant reputational and operational risks for the company in the North American market. Market analysts suggest that the potential loss of government contracts and mounting legal liabilities could exert significant downward pressure on Grifols' stock performance.